Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

On Drug Price Increases, Pfizer's Read Expects ‘Business As Normal’ In 2019

Executive Summary

Presiding over his last earnings call as the CEO of Pfizer, Ian Read was pressed about the company's drug pricing strategy for 2019 amid push back from the Trump Administration.

You may also be interested in...



Medicare's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues

President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.

Pfizer CEO Read Will Pass The Torch To Bourla In 2019

Chief Operating Officer Albert Bourla will succeed Ian Read as CEO of Pfizer, taking over the top spot at a steady point in the big pharma's evolution. Bourla's near-term challenges will be navigating the loss of Lyrica and the changing US health care dynamics.

HHS Advancing Attack On Rebates With Proposal To Revoke Safe Harbor

Upcoming proposed rule could also provide new anti-kickback safe harbor to facilitate value-based contracts, as manufacturers and payers have urged.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel